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Mutations in Novel Peroxin Gene PEX26 That Cause Peroxisome-Biogenesis
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The human disorders of peroxisome biogenesis (PBDs) are subdivided into 12 complementation groups (CGs).
CG8 is one of the more common of these and is associated with varying phenotypes, ranging from the most severe,
Zellweger syndrome (ZS), to the milder neonatal adrenoleukodystrophy (NALD) and infantile Refsum disease
(IRD). PEX26, encoding the 305-amino-acid membrane peroxin, has been shown to be deficient in CG8. We studied
the PEX26 genotype in fibroblasts of eight CG8 patients—four with the ZS phenotype, two with NALD, and two
with IRD. Catalase was mostly cytosolic in all these cell lines, but import of the proteins that contained PTS1, the
SKL peroxisome targeting sequence, was normal. Expression of PEX26 reestablished peroxisomes in all eight cell
lines, confirming that PEX26 defects are pathogenic in CG8 patients. When cells were cultured at 30C, catalase
import was restored in the cell lines from patients with the NALD and IRD phenotypes, but to a much lesser extent
in those with the ZS phenotype, indicating that temperature sensitivity varied inversely with the severity of the
clinical phenotype. Several types of mutations were identified, including homozygous G89R mutations in two
patients with ZS. Expression of these PEX26 mutations in pex26 Chinese hamster ovary cells resulted in cell
phenotypes similar to those in the human cell lines. These findings confirm that the degree of temperature sensitivity
in pex26 cell lines is predictive of the clinical phenotype in patients with PEX26 deficiency.
Introduction
Peroxisomes are single-membrane–bounded ubiquitous
organelles present in a wide variety of eukaryotic cells.
The significance of peroxisomal function is highlighted
by the severity of clinical manifestations of the human
genetic peroxisome-biogenesis disorders (PBDs [MIM
601539]), in which various metabolic pathways, such
as b oxidation of very-long-chain fatty acids and the
synthesis of plasmalogens (van den Bosch et al. 1992),
are impaired. The PBDs include Zellweger syndrome
(ZS [MIM 214100]), neonatal adrenoleukodystrophy
(NALD [MIM 202370]), infantile Refsum disease (IRD
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[MIM 266510]), and rhizomelic chondrodysplasia punc-
tata (RCDP [MIM 215100]) (Lazarow and Moser 1995).
Patients with ZS have severe nervous-system deficits and
characteristic dysmorphic features and rarely live beyond
the 1st year. Patients with NALD and IRD have abnor-
malities that resemble ZS but are less severe. The three
disorders are now considered to form a clinical continu-
um, with ZS the most severe, NALD intermediate, and
IRD the least severe. Patients with NALD and IRD survive
to early childhood and occasionally to the 3rd decade or
later (Lazarow and Moser 1995). Patients with RCDP
show distinct phenotypic characteristics, such as severe
growth failure and rhizomelia. Genetic heterogeneity con-
sisting of 12 complementation groups (CGs) has been
identified in PBDs (Fujiki 2000; Ghaedi et al. 2000; Mat-
sumoto et al. 2001). The primary cause for PBDs is the
impaired biogenesis of peroxisomes (Fujiki 2000; Gould
and Valle 2000).
Import of peroxisomal matrix proteins is mediated
by two types of peroxisomal targeting signals (PTSs):
the C-terminal uncleavable tripeptide PTS1, -S/A/C-K/
R/H-L/(M), identified in many enzymes (e.g., acyl-CoA
oxidase [AOx]); and the cleavable nonapeptide prese-
quence PTS2, -(R/K)(L/V/I)X5(H/Q)(L/A)- (“X” denotes
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any amino acid), located at the N-terminus in proteins
(e.g., 3-ketoacyl-CoA thiolase [hereafter referred to as
“thiolase”]).
We previously isolated 13 CGs of peroxisome-biogene-
sis–defective Chinese hamster ovary (CHO) cell mutants,
including ZP167 of CG8 (Ghaedi et al. 1999), mostly by
the 9-(1′-pyrene)nonanol (P9OH)/UV selection method
(Morand et al. 1990; Shimozawa et al. 1992). All CHO
cell mutants resembled fibroblasts from patients with
PBDs in that they showed defects in peroxisome assem-
bly, despite normal synthesis of peroxisomal proteins.
Complementation studies showed that 10 of the mutants
corresponded to 10 of the 12 human CGs, whereas 3
were distinct (Fujiki 2000; Ghaedi et al. 2000). We have
so far isolated or identified nine peroxin cDNAs—in-
cluding PEX1, PEX2, PEX3, PEX5, PEX6, PEX7,
PEX12, PEX14, and PEX19—by genetic strategies, such
as functional phenotype-complementation assays using
CHO cell mutants (Fujiki 2000; Mukai et al. 2002). Fur-
thermore, 11 PEX genes required for peroxisome bio-
genesis—PEX1, PEX2, PEX3, PEX5, PEX6, PEX7,
PEX10, PEX12, PEX13, PEX16, and PEX19—have
been demonstrated as the genetic cause responsible for
PBD CGs: CG1 (CG-E), CG10 (CG-F), CG12 (CG-G),
CG2, CG4 (CG-C), CG11 (CG-R), CG7 (CG-B), CG3,
CG13 (CG-H), CG9 (CG-D), and CG14 (CG-J), respec-
tively (with the U.S./European and Japanese names, the
latter given in parentheses) (Fujiki 2000; Ghaedi et al.
2000; Gould and Valle 2000; Matsumoto et al. 2001;
Mukai et al. 2002).
Only the genetic cause for CG8 (CG-A) PBDs had
remained unidentified for over a decade. Very recently,
we have isolated the novel peroxin Pex26p cDNA, en-
coding 34-kDa peroxisomal membrane protein, by a ge-
netic phenotype-complementation cloning strategy us-
ing a CHO cell mutant, ZP167 of CG8 (Matsumoto et
al. 2003). PEX26 expression also complemented the
impaired catalase import in fibroblasts from a CG8 pa-
tient with NALD. However, molecular and biochemical
defects in peroxisome biogenesis that underlie the dif-
ference in severity between the CG8 PBDs (ZS, NALD,
and IRD) remained undefined. In the present study, we
report that the import of catalase and PTS2 proteins,
such as thiolase, is temperature sensitive (TS) in cells
from patients with NALD and IRD but far less so in
CG8 patients with the ZS phenotype.
Material and Methods
Cell Culture and DNA Transfection
Several skin fibroblast cell lines from CG8 patients
with PBDs—including ZS GM07371, IRD GM08771,
and NALD GM11335—were obtained from the Coriell
Institute for Medical Research. Fibroblasts from Jap-
anese CG-A (CG8) patients with ZS (A-02 and A-06)
were from Gifu University (Imamura et al. 1998b); those
from patients GM16865, GM16866, and PDL35167
were from the Kennedy-Krieger Institute. Fibroblasts
from an unaffected control individual and CG8 patients
with PBD were cultured at 37C or 30C in Dulbecco’s
modified Eagle medium high glucose supplemented with
10% fetal calf serum (Shimozawa et al. 1992; Imamura
et al. 1998a; Tamura et al. 2001). CHO cell mutant
ZP167 of CG8 (Ghaedi et al. 1999) was cultured at 37C
or 30C, as described elsewhere (Tamura et al. 2001).
DNA transfection to CHO cells and patient fibroblasts
was respectively performed by using Lipofectamine (Life
Technologies) and by electroporation using a Gene Puls-
er II electroporator (Bio-Rad) on setting at 320 V and
500 mF, as described elsewhere (Tamura et al. 1998).
Human PEX26 cDNA (GenBank accession number
AB089678) was cloned by a functional complemen-
tation assay using CHO cell mutant ZP167 and a hu-
man kidney cDNA library constructed in pCMVSPORT
(Tamura et al. 1998; Matsumoto et al. 2003).
Morphological Analysis
Peroxisomes in human fibroblasts and CHO cells were
visualized by indirect immunofluorescence light micros-
copy, as described elsewhere (Shimozawa et al. 1992). We
used rabbit antibodies to each of the following: human
catalase (Matsumoto et al. 2001), PTS1 peptide (Otera
et al. 1998), thiolase (Tsukamoto et al. 1990), and Pex14p
C-terminal peptide (Shimizu et al. 1999). Antigen-anti-
body complexes were detected under a Carl Zeiss Axi-
oskop FL microscope, using fluorescein isothiocyanate–
labeled goat anti-rabbit immunoglobulin G (IgG) anti-
body (Cappel) or Texas Red–labeled goat anti-rabbit IgG
antibody (Leinco Technologies). A stable transformant,
named “ZP167EG2,” of ZP167 cells expressing PTS2-
tagged enhanced green fluorescent protein (PTS2-EGFP)
was isolated, essentially as described by Yanago et al.
(2002). PTS2 import was verified by monitoring the
EGFP localization.
Mutation Analysis
Poly(A) RNA was obtained from patient fibroblasts
by using a QuickPrep mRNA purification kit (Amersham
Biosciences). RT-PCR using poly(A) RNA was conduct-
ed with a pair of human PEX26-specific PCR forward
and reverse primers—1F (nucleotide sequence at 4–21)
and 1R (nucleotide sequence at 915–898) or -1F (nucleo-
tide sequence at 20 to 1) and 1R (table 1)—to cover
a full-length PEX26 ORF. Nucleotide sequence of the
PCR products cloned into pGEM.T easy vector (Pro-
mega) was determined by the dideoxy-chain termination
method using a Dye-terminator DNA sequence kit (Ap-
plied Biosystems). Patient-derived PEX26 cDNAs—in-
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Table 1
Synthetic Oligonucleotide Primers Used
Primera
Sequenceb
(5′r3′)
1F AAGCTTGAGATCTCTAAGAGCGATTCTTCGACC [4–21]
-1F GCCTTGGACCCGGACTCGTT [20 to 1]
1R CAGGGAAGATCTGTCACGGATGCGGAGCTG [915–898]
2F AAGTCCTGGAGCTGTGCA [356–373]
-2F ACAGAAGGCGATGGGCCGAG [206 to 187]
2R GCTGGATCAAATCTCACC [815–798]
3R CACAGCTCCAGGCTCTTG [411–394]
97F CTGGAGATCTCTGATCGGTGGCAAGAAGTC
Not.R GCCCGCGGCCGCTCAGTCACGGATGCGGAG [915–901 plus stop codon]
g1F TTCTGCTGACAGCTCATTGG
g1R ACTTACCACAGCTCCAGGAC
g3F GCGGTCACTCCGACGTCTGAGGACCTGGGC
g3R GCCCGGAAATCGGTTCATTTCCGAGCCCAG
T35insCF CTGCAGCCCCCCCTCAGGGGGCTCGGGG
T35insCR CCCTGAGGGGGGGCTGCAGAGGTCGAAG
e1F AACTCGGGATATCCCGGAGCCTCTGGGGAG
e1R TGGGAAGGACAGAACTCCTGAGACCTTGAG
SP6 ATTTAGGTGACACTATAG
a F p forward primer; R p reverse primer.
b Positions of the underlined nucleotide sequences are given in brackets.
cluding PEX26G89R, PEX26R98W, PEX26L45P, and
PEX26G255insT—were cloned into pCMVSPORT I
vector by replacing the BssHII-PmaCI fragment (nucleo-
tide sequence at 75–487) of PEX26 from a control in-
dividual with that of the respective patient’s PEX26 in
pGEM.T easy. PEX26M1T was constructed as follows:
PCR was done using as template the RT product from
GM08771 RNA and primers -2F and 3R; the EcoRV-
BssHII fragment was inserted into EcoRV-BssHII sites of
pCMVSPORT•PEX26. pCMVSPORT•PEX26T35insC
was generated by two-step PCR: the first PCR was done
with sets of SP6 and T35insC.R, and T35insC.F and 3R;
the second PCR was done with SP6 and 3R. Its SalI-
BssHII fragment was cloned into the SalI-BssHII site of
pCMVSPORT•PEX26. pCMVSPORT•PEX26T35insC/
del223-271 was constructed by replacing the PmaCI-
BamHI fragment of pCMVSPORT•PEX26T35insC with
that of PEX26del223-271 in pGEM.T. Transfection was
done to fibroblasts by electroporation and to ZP167 by
lipofection. Genomic DNA was prepared from cultured
fibroblasts, as described elsewhere (Honsho et al. 1998).
To investigate the zygosity of a PEX26 mutant allele, we
performed PCR amplification using a pair of forward and
reverse primers: g1F and g1R for the nucleotide residues
at 231–371 in the PEX26 ORF and g3F and g3R for the
nucleotide residues at 1–230 of PEX26 ORF (table 1).
PCR products were directly sequenced.
Generation of Mutant Constructs
An epitope Flag-tagging to the N-terminus of Pex26p
was done as follows. The full-length PEX26 was am-
plified using a pair of primers: 1F and Not.R for nucle-
otide sequence at 915–901. The PCR product was di-
gested with BglII and NotI and was then ligated in-
to the BamHI-NotI sites of pCMVSPORT•Flag-PEX1
(Tamura et al. 2001). A Flag-PEX26 mutant, Flag-
PEX26T35insC, was likewise constructed from PCR
product by using primers 1F and Not.R and, as a tem-
plate, pCMVSPORT•PEX26T35insC. Flag-PEX26M1T
was constructed as follows: PCR was done using primers
97F (designed for translation starting at the second Met,
at position 97) and Not.R. The BglII-NotI fragment of
PCR product was ligated into the BamHI-NotI sites of
pCMVSPORT•Flag-PEX1. Flag-tagged PEX26 mu-
tants in pCMVSPORT—PEX26G89R, PEX26R98W,
PEX26L45P, and PEX26G255insT—were generated
by replacing the BssHII-PmaCI fragment (nucleotide se-
quence at 75–487) of PEX26 from a control individual
with the respective patient’s PEX26 in pGEM.T easy.
Other Methods
Western blot analysis was done using a set of primary
rabbit antibodies and a second antibody, donkey anti-
rabbit IgG antibody conjugated to horseradish peroxi-
dase (Amersham Biosciences), or using mouse anti-Flag
antibody (M2; Sigma) and horseradish peroxidase-
labeled donkey anti-mouse IgG antibody (Amersham
Biosciences). A multiple-tissue northern blot (Clontech)
was probed with 32P-labeled PEX26 cDNA amplified
with primers 2F and 2R and full-length b-actin cDNA
(Clontech). Washing was done twice with 0.1 # SSPE
Figure 1 Phenotype of peroxisome deficiency in fibroblasts from CG8 patients. A, Patient-derived fibroblasts, cultured for 3 d at 37C or
30C and then stained with antibodies to catalase (a–f), PTS1 (g–l), a PTS2 protein (thiolase) (m–r), and Pex14p (s–x). Fibroblasts were derived
from a patient with ZS (GM07371) (left panels), a patient with NALD (PDL35167) (middle panels), and a patient with IRD (GM08771) (right
panels). Magnification 630#; bar p 30 mm. B, Biogenesis of peroxisomal proteins. Fibroblasts (∼105 cells) from a normal control individual and
from CG8 patients with PBDs were cultured for 3 d at 37C or 30C. Cell lysates were subjected to SDS-PAGE and were transferred to a polyvinylidene
difluoride membrane. Immunoblot analysis was done using rabbit antibodies to AOx (upper panel) and thiolase (lower panel). Lanes 1 and 2,
Normal control (N.C.). Lanes 3 and 4, Patient with ZS (GM07371). Lanes 5 and 6, Patient with NALD (PDL35167). Lanes 7 and 8, Patient with
IRD (GM16865). Molecular markers are at left. “A,” “B,” and “C” denote 75-, 53-, and 22-kDa AOx components, respectively. The dot (•) shows
a nonspecific band (Tamura et al. 2001). “P” and “M” denote a larger precursor protein and a mature protein of thiolase, respectively. C, PEX26
expression, restoring the impaired protein import to peroxisomes in PBD fibroblasts. GM07371 fibroblasts were transfected with PEX26 and were
stained as in panel A, 3 d after the transfection. Bar p 30 mm.
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Table 2
Phenotypes and Genotypes of Fibroblasts from CG8 Patients with PBDs
PATIENT (SEX)
AGE AT DEATH
OR LAST
FOLLOW-UP
TSa OF
(%)
Catalase PTS1
Thiolase
(PTS2) MUTATION(S)
37C 30C 37C 30C 37C 30C
RT-PCR [Clones]b
(ntraa) Genomic PCR
ZS GM07371 (F) 3 wk 0 0 80 90 0 0 T35insCrfs/ter [12/12] T35insC/T35insC
T35insC/del223-271 [6/12] …c
ZS A-02 (M) 11 mo 0 15 100 100 0 10 G265ArG89R [12/12] G265A/G265A
ZS A-06 (F) 4 mo 0 15 100 100 0 5 G265ArG89R [12/12] G265A/G265A
ZS GM16866d 14 wk gestation 0 5 80 90 0 20 …e …e
NALD GM11335 (F) 6 years 15 65 100 100 30 70 C292TrR98Wf [10/10] C292T/C292T
NALD PDL35167 (M) 10 years 5 50 100 100 50 90 C292TrR98W [11/11] C292T/C292T
IRD GM08771 (F) 4 years 10 40 100 100 60 90 T2CrM1T [3/12] T2C/T2
T134CrL45P [9/12] T134C/T134
IRD GM16865 (F) 12 years 15 70 100 100 30 80 C292TrR98W [10/16] C292T/C292
G255insTrfs/ter [6/16] G255insT/G255
Control 100 100 100 100 100 100
a The percentage of peroxisome-positive cells was the mean of total cell number counted in two separate areas under a microscope, where
the range was ∼10% of respective mean values.
b nt p Nucleotide; aa p amino acid; fs/ter p frameshift resulting in termination.
c Not determined.
d Sex of fetus not checked.
e No RT-PCR products were obtained.
f Matsumoto et al. 2003.
(15 mM NaCl, 0.865 mM NaH2PO4, and 0.125 mM
EDTA)/0.1% SDS at 55C.
Results
Normal Import of PTS1—and TS Catalase and PTS2
Import in CG8 Fibroblasts
Catalase was detected in a diffuse staining pattern,
indicative of cytosolic localization, in fibroblasts derived
from a CG8 patient with ZS (GM07371) at 37C (fig.
1A [a]), whereas cells of several patients, including
NALD PDL35167 and IRD GM08771, were positive
but with many fewer catalase-containing particles (fig.
1A [c and e]) than in normal cells (data not shown).
Catalase was likewise localized in the cytosol in fibro-
blasts from the other three CG8 patients with ZS (table
2). When cultured for 3 d at 30C, fibroblasts from all
of the patients with NALD and IRD were morpholog-
ically restored for catalase import or showed the increase
in number of catalase-positive particles (fig. 1A [d and
f ]), indicative of the morphological TS phenotype. In
ZS-type fibroblasts, at 30C, catalase was not imported
(e.g., in fibroblasts from patient GM07371; see fig. 1A
[b]) or was restored only slightly (e.g., in fibroblasts from
patient A-02; see table 2). In contrast, PTS1 proteins
were observed in numerous punctate structures in fibro-
blasts derived from all of the patients with the three types
of CG8 PBDs examined, at both temperatures (fig. 1A
[g–l]), suggesting normal import of PTS1 proteins into
peroxisomes. In ZS fibroblasts, thiolase, a PTS2 pro-
tein, was detected in a cytosolic staining pattern, indi-
cating that PTS2 import was affected (fig. 1A [m]). In
fibroblasts from two patients with IRD (GM08771 and
GM16865) and a patient with NALD (PDL35167), thi-
olase was discernible in a punctate staining pattern, in-
dicative of normal but less efficient PTS2 import (fig. 1A
[o and q] and table 2). By shifting to 30C, we increased
thiolase-positive peroxisomes in number in PTS2-posi-
tive cells from patients with NALD and IRD (fig. 1A [p
and r] and table 2). Pex14p-positive particles were seen
at both temperatures in all of the CG8 PBD fibroblasts
(fig. 1A [s–x]), indicative of normal import of peroxi-
somal membrane proteins. In fibroblasts from an unaf-
fected control individual, numerous peroxisomes were
present at both temperatures (table 2).
In mammals, AOx is synthesized as a 75-kDa polypep-
tide, named the “A” component, and is proteolytically
converted into 53-kDa “B” and 22-kDa “C” polypeptide
components in peroxisomes (Miyazawa et al. 1989; Shi-
mozawa et al. 1992). AOx components (A–C) were evi-
dent in normal fibroblasts cultured at 37C, as well as at
30C (fig. 1B, upper panel [lanes 1 and 2]). AOx-A–C
components were likewise detectable in fibroblasts from
patients with PBDs (namely, NALD PDL35167 and IRD
GM16865) at 37C and more strongly at 30C (fig. 1B
[lanes 5–8]), at which temperature PTS1 and PTS2 pro-
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Table 3
CGs of Patients with PBDs and PEX Genes
U.S./European (Japanese)
CG Designation Phenotype(s)a Gene
CG8 (CG-A) ZS, NALD,b,c IRDb,c PEX26
CG1 (CG-E) ZS, NALD, IRDc,d,e PEX1
CG2 ZS, NALD PEX5
CG3 ZS, NALD, IRD PEX12
CG4f (CG-C) ZS, NALDc PEX6
CG7g (CG-B) ZS, NALD PEX10
CG9 (CG-D) ZS PEX16
CG10 (CG-F) ZS, IRDc PEX2
CG11 (CG-R) RCDP PEX7
CG12 (CG-G) ZS PEX3
CG13 (CG-H) ZS, NALDh PEX13
CG14 (CG-J) ZS PEX19
a Cell phenotypes showing reported TS protein import to
peroxisomes are also indicated.
b Present study.
c Imamura et al. 1998b.
d Imamura et al. 1998a.
e Walter et al. 2001.
f Including former CG6.
g Including former CG5.
h Shimozawa et al. 1999.
Figure 2 (p. 239) Mutation analysis of PEX26 in CG8 patients with PBDs. A, Deduced amino acid sequence alignment of human
(Hs) and mouse (Mm) Pex26p. For human and mouse PEX26 cDNAs, see GenBank (accession numbers AB089678 and AK014598, respectively).
Dashes (–) represent spaces. A membrane-spanning segment is indicated by a line above it. B, Mutation analysis by PCR. Left, Nucleotide
sequence of PEX26 from CG8 patients with PBDs, determined by RT-PCR. Partial sequence and deduced amino acid sequence of PEX26
cDNAs from a normal control and patients with ZS (GM07371 and A-02) and IRD (GM08771 and GM16865) are shown. RT-PCR products
from GM16865 also showed the R98W mutation (see table 2). Right, PCR for control DNA and patient-derived fibroblasts. Nucleotide sequence
of PCR products was determined. The nucleotide sequence for DNA from patients (A-02 and GM16865) was determined for the sense strand
(above). Mutations identified were deposited in GenBank: T35insC (accession number AB103104), T35insC/del223-271 (accession number
AB103105), G89R (accession number AB103106), R98W (accession number AB103107) (Matsumoto et al. 2003), M1T (accession number
AB103108), L45P (accession number AB103109), and G255insT (accession number AB103110).
teins were mostly in punctate structures, which were per-
oxisomes (see fig. 1A [i–l and o–r] and table 2). In con-
trast, in fibroblasts from patient ZS GM07371, conver-
sion of AOx-A to AOx-B and -C components was un-
detectable at 37C but became barely discernible at 30C,
whereas PTS1 proteins were in punctate structures at both
temperatures, presumably in peroxisomal-remnant–like
particles (see fig. 1A [g and h]). A protease required for
AOx conversion may not be imported or may be much
less functional in these cells. Peroxisomal thiolase is syn-
thesized as a larger, 44-kDa precursor with an amino-
terminal cleavable PTS2 and is processed to its mature
size, 41 kDa, in peroxisomes (Tsukamoto et al. 1990;
Shimozawa et al. 1992; Mukai et al. 2002). In normal
fibroblasts, only the mature thiolase was detected at both
temperatures (fig. 1B, lower panel [lanes 1 and 2]),
thereby demonstrating rapid processing of the precursor
form. The mature form was likewise detectable at both
temperatures in NALD PDL35167 cells (fig. 1B, lower
panel [lanes 5 and 6]), in which most of the thiolase was
apparently imported (see fig. 1A [o and p] and table 2).
In contrast, only the larger precursor was found at 37C
in ZS GM07371 fibroblasts (fig. 1B, lower panel [lane
3]), implying a defect of thiolase import and processing
activity. Only partial processing was noted at 30C (fig.
1B, lower panel [lane 4]). The thiolase precursor was
mostly processed to the mature form at 30C in IRD
GM16865 fibroblasts (fig. 1B, lower panel [lane 8]),
whereas both forms of thiolase were detectable at 37C,
but only at a very low level (fig. 1B, lower panel [lane
7]). The extent of thiolase processing thus is apparently
consistent with the morphological TS phenotype of thio-
lase import (see fig. 1A [m–r] and table 2).
Fibroblasts from patient ZS GM07371 were morpho-
logically complemented for peroxisome assembly at 37C
by transfection of PEX26 (fig. 1C). The import of perox-
isomal proteins was likewise restored in fibroblasts de-
rived from CG8 patients with PBDs, including those from
patients NALD PDL35167 and IRD GM16865 (data not
shown). These results indicate that dysfunction of PEX26
is responsible for the impaired biogenesis of peroxisomes
in CG8 patients (table 3).
Identification of Mouse PEX26
By a homology search of the mouse DNA database,
using “human PEX26” as a search term, we identified a
potential mouse homologue (GenBank accession number
AK014598). Mouse and human PEX26 proteins were
identical in amino acid length, with 74% identity at an
amino acid level, despite demonstration that a 4-amino-
acid deletion was mutually aligned at two different places
(fig. 2A).
Mutation Analysis of CG8 Patients
Patients with ZS: T35insC.—To characterize the dys-
function of PEX26 in CG8 patients with ZS, we iso-
lated PEX26 cDNA from fibroblasts from a patient
(GM07371) and an unaffected control individual by
means of RT-PCR. Subsequent sequencing of cDNA
clones from the patient indicated a point mutation re-
sulting in a 1-base (C) insertion at nucleotide position
T35 (with the A of the initiating ATG being 1), in a
codon (CTC) for Leu12, resulting in a frameshift in-
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Figure 3 (p. 241) Transformation of a CHO pex26 mutant (ZP167) with patient’s PEX26. A, Schematic representation of Pex26p
and mutation sites in patients with PBDs. “TM” designates a membrane-spanning segment. B, PEX26 cDNAs derived from CG8 patients with
PBDs, transfected to ZP167. Transfection was done with ZS GM07371–derived PEX26T35insC (a and h) and PEX26T35insC/del223-271 (b
and i), ZS A-02–derived PEX26G89R (c and j), NALD PDL35167–derived PEX26R98W(d and k), IRD GM08771–derived PEX26M1T (e
and l) and PEX26L45P (f and m), and IRD GM16865–derived PEX26G255insT (g and n). Cells were cultured for 3 d at 37C (panels a–g)
or 30C (h–n) and were stained with anti-catalase antibody. Magnification 630#; bar p 20 mm. C, ZP167EG2 cells expressing PTS2-EGFP,
likewise transfected with PEX26G89R (left) and PEX26R98W (right). Import of proteins with PTS1 and PTS2 was verified by cell staining
with anti-PTS1 antibody and by monitoring of PTS2-EGFP. Bar p 20 mm. D, Biogenesis of AOx and thiolase. Cell lysates (∼104 cells) of
PEX26G89R- or PEX26R98W-transfected ZP167 that had been cultured for 3 d at 37C (lanes 1, 3, and 5) or 30C (lanes 2, 4, and 6) were
analyzed by immunoblot, using antibodies to AOx (left) and thiolase (right). Molecular markers are given at left. “A”–“C” denote AOx
components. Dots (•) show nonspecific bands. “P” and “M” denote a larger precursor protein and a mature protein of thiolase, respectively.
ducing a 102-amino-acid sequence distinct from nor-
mal Pex26p (fig. 2B, left panel). Of 12 cDNA clones
isolated, all showed the same site mutation, termed
“PEX26T35insC,” thereby suggesting a homozygous
mutation. Furthermore, six clones showed an addition-
al mutation: deletion of nucleotide residues at 668–
814, encoding amino acid residues at 223–271 (fig.
2B, left panel).
To determine the zygosity of a mutant allele, we per-
formed genomic PCR to amplify the sequence corre-
sponding to nucleotide residues 1–230 in the PEX26
ORF. Only a single type of nucleotide sequence giving
rise to the T35insC mutation was identified in the PCR
products (fig. 2B, right panel). A PEX26 mutation re-
sulting in the deletion of amino acid residues at 223–271
was not defined. Taken together, these findings—namely,
T35insC and T35insC plus a mutation responsible for
deletion of 223–271—make it likely that this patient
with ZS was a compound heterozygote. PEX26T35insC
was functional in catalase import (figs. 3A and 3B [a
and h]), as well as in transport of PTS1 and PTS2 pro-
teins (table 4), which resulted in formation of perox-
isomes, as assessed by transfection to a pex26 ZP167
mutant and ZP167EG2 cells expressing PTS2-EGFP. Ex-
pression of PEX26T35insC/del223-271 in ZP167 gave
restoration of peroxisomes very weakly at 37C and
more efficiently at 30C (fig. 3B [b and i] and table 4).
Cotransfection of PEX26T35insC and PEX26T35insC/
del223-271 to ZP167 showed a phenotype similar to
GM07371 fibroblasts, only in PTS1 import (table 4).
Weak catalase import and positive PTS2 import may
be due to a higher level of expression of these two types
of Pex26p mutants.
Patients with ZS: G89R.—RT-PCR was likewise
done using poly(A) RNA from another CG8 patient
with ZS (A-02; Gifu University). Sequencing of cDNA
clones showed a point mutation of nucleotide G to A
at position 265 in a codon (GGG) for Gly89, resulting
in a codon (AGG) for Arg (fig. 2B, left panel). Of 12
cDNA clones isolated, all showed the same mutation,
termed “PEX26G89R,” thereby suggesting a homo-
zygous mutation. Exactly the same mutation at nucleo-
tide substitution G265A, resulting in missense G89R
mutation, was identified in the RT-PCR products from
fibroblasts from an unrelated patient with ZS (A-06)
(table 2). To determine the zygosity of a PEX26G89R
mutant allele in these two patients with ZS, we per-
formed genomic PCR to amplify the sequence corre-
sponding to nucleotide residues 231–371 in the PEX26
ORF. Only a single type of nucleotide sequence with
G265A was identified in the PCR products from both
patients (fig. 2B, right panel, and table 2), indicating
that the patients with ZS (A-02 and A-06) were ho-
mozygous for the G89R mutation. This mutation in-
activated the function of PEX26, as assessed by trans-
fection of PEX26G89R to CHO cell mutant ZP167,
which resulted in the phenotype of deficiency with
weak TS import of catalase and PTS2-EGFP (figs. 3B
[c and j] and 3C, left panel [b and d], and table 4) and
in TS-dependent PTS1 import that was competent but
less potent (fig. 3C, left panel [a and c], and table 4),
similar to that of the patient-derived fibroblasts. Bio-
genesis of peroxisomal proteins, AOx and thiolase, was
verified in PEX26G89R-transfected ZP167 cells. Con-
version of AOx-A to AOx-B and -C components and
processing of thiolase were detected only in cells cul-
tured at 30C (fig. 3D [lanes 3 and 4]), reproducing a
TS phenotype as noted in morphology in ZP167 ex-
pressing Pex26pG89R (and patient fibroblasts), where-
as ZP167 transfected with normal PEX26 showed such
proteolytic changes at both temperatures (fig. 3D [lanes
1 and 2]). These findings imply the importance of the
N-terminal part encompassing Arg89 of Pex26p in its
biological activity. It is plausible that the GrR missense
mutation may affect the configuration of Pex26p.
From poly(A) RNA from another CG8 patient with
ZS (GM16866), no detectable RT-PCR product was ob-
tained (table 2), indicating that PEX26 mRNA was un-
der the detection level. PEX26 may be defective at the
level of transcription, or it may be expressed but unstable
and degraded.
Patients with NALD: R98W.—To determine the
dysfunction of PEX26 in a CG8 patient with NALD
(PDL35167), we cloned and sequenced RT-PCR prod-
ucts. Of 11 cDNA clones isolated, all showed a point
mutation of nucleotide C to T at position 292 in a
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Table 4
Transfection of Patient-Derived PEX26 to CHO pex26 Mutant ZP167
PEX26 MUTANT
TSa OF
(%)
Catalase PTS1 PTS2-EGFPb
37C 30C 37C 30C 37C 30C
Wild typec 100 100 100 100 100 100
T35insC 70 90 90 90 90 90
T35insC/del223-271 5 10 5 45 5 20
G89R 0 5 5 55 0 10
R98W 5 70 65 85 100 100
M1T 55 70 60 95 60 80
L45P 0 0 0 5 0 0
G255insT 0 40 70 90 75 75
Coexpression:
T35insC  T35insC/del223-271 5 20 85 80 80 80
M1T  L45P 50 70 55 90 100 100
R98W  G255insT 0 60 70 85 90 90
a The percentage of peroxisome-positive cells was the mean of total cell number counted in two
separate areas under a microscope, where the range was ∼10% of respective mean values.
b PTS2 import was assessed with PTS2-tagged EGFP.
c Of the cells, 60%–80% complemented by PEX26 transfection; import-restoring activity of
PEX26 mutants was represented as a percentage of normal Pex26p.
codon (CGG) for Arg98, resulting in a codon (TGG)
for Trp, termed “PEX26R98W” (data not shown),
strongly suggesting that the patient is homozygous for
the PEX26R98W allele, which is the same missense
mutation recently identified in another patient with
NALD (GM11335) (Matsumoto et al. 2003) (table 2).
PCR and sequence analysis of the PDL35167 genomic
sequence, encompassing nucleotide residues 231–371
in the PEX26 ORF, showed one type of nucleotide sub-
stitution, C292T (table 2), indicating that this patient
with NALD was homozygous for the mutation as iden-
tified for GM11335 (Matsumoto et al. 2003).
Expression of PEX26R98W in pex26 ZP167 resulted
in a morphological phenotype similar to that seen in the
patient’s fibroblasts in regard to import of catalase and
PTS1 and PTS2 proteins (figs. 3B [d and k] and 3C,
right panel, and table 4), confirming that PEX26R98W
is the cause of NALD in these patients with PBDs. Bio-
genesis of AOx and thiolase in PEX26R98W-transfect-
ed ZP167 cells was similar to that in ZP167 expressing
normal PEX26, showing that this is a milder form of
the PEX26 mutation (fig. 3D [lanes 5 and 6]).
Patients with IRD: M1T/L45P.—To delineate the dys-
function of PEX26 in the CG8 patients with IRD, we
sequenced PEX26 cDNA cloned by RT-PCR from fibro-
blasts from a patient (GM08771), and we detected two
types of point mutations: nucleotide T to C at position 2
in a codon (ATG) for the initiator Met1 and at position
134 in a codon (CTG) for Leu45, resulting in Thr1 and
Pro45, respectively (fig. 2B, left panel). Of 12 cDNA clones
isolated, 3 were with T2C, termed “PEX26M1T,” and 9
were with T134C, termed “PEX26L45P,” thereby sug-
gesting a compound heterozygous mutation. To confirm
the mutation sites and zygosity of mutant alleles, we per-
formed genomic PCR at nucleotide residues 1–230 in the
PEX26 ORF. Two nucleotide substitutions were identi-
fied: one at position 2, T2C, together with normal T2;
the other at T134C, with normal T134 (fig. 2B, right
panel). We interpreted the results to mean that this patient
with IRD (GM08771) was a compound heterozygote for
the mutations.
PTS1-, catalase-, and PTS2-positive particles were dis-
cernible, in a mildly TS manner in the PTS1 and catalase
import, in PEX26M1T-transfected ZP167 cells, whereas
PEX26L45P expression did not restore the impaired
peroxisome biogenesis in ZP167 (fig. 3B [e, f, l, and m]
and table 4). An ∼26-kDa protein band was detected
using antibody to a Pex26p C-terminal peptide (data not
shown), suggesting that Pex26pM1T was translated at
the second Met, at position 96. In ZP167 cells that had
been cotransfected with PEX26M1T and PEX26L45P,
the morphological phenotype was similar to those of
PEX26M1T-transfected cells and fibroblasts from pa-
tient GM08771, implying that PEX26M1T expression
represents the phenotype of the patient-derived cells (ta-
ble 4). It is less likely that Pex26pL45P affects on import
of catalase and PTS1 and PTS2 proteins as a dominant-
negative Pex26p.
Patients with IRD: R98W/G255insT.—In PEX26
cDNA likewise isolated from fibroblasts from patient
IRD GM16865, we identified a point mutation of nu-
cleotide C to T at position 292, resulting in R98W, as
in patients with NALD (table 2). Of 16 cDNA clones
isolated, only 10 showed the same mutation, thereby
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Figure 4 Expression level of Pex26p. ZP167 cells transfected with Flag-PEX26 and its variants from CG8 patients were cultured for 3 d at
37C (left) or 30C (right). Cell lysates (∼104 cells) were analyzed by SDS-PAGE and immunoblot, using anti-Flag antibody. Blackened arrowheads
indicate the migration of Pex26p with authentic size; unblackened arrowheads indicate truncated forms of Pex26p.
suggesting a heterozygous mutation; the remaining 6
cDNA clones showed a point mutation resulting in a
1-base (T) insertion at nucleotide position 255 in a
codon (CTG) for Leu85, named “PEX26G255insT,”
resulting in a frameshift inducing a 28-amino-acid
sequence distinct from normal Pex26p (fig. 2B, left
panel), in which the sequence at nucleotide position
292 was normal. These results indicate that patient
GM16865 is a compound heterozygote. Zygosity of
mutant alleles was assessed by genomic PCR at nucleo-
tide residues 231–371 in the PEX26 ORF. Two nucleo-
tide substitutions were identified: C292T (not shown)
and G255insT, both together with normal sequence
(fig. 2B, right panel), confirming that this patient with
IRD (GM16865) was a compound heterozygote for the
mutations. PEX26G255insT expression in ZP167 re-
sulted in TS-dependent catalase import (fig. 3B [g and
n]), as well as PTS1- and PTS2-positive particles (ta-
ble 4), similar to the phenotype of patient GM16865.
Coexpression of PEX26R98W and PEX26G255insT
also showed a similar morphology (table 4).
Collectively, these data demonstrate that the dysfunc-
tion of PEX26 is responsible for peroxisome deficiency
in CG8 PBDs.
Expressed Level of Mutated Pex26p
To investigate the expression level of Pex26p in nor-
mal cells and to determine to what extent the identified
mutant forms of Pex26p are expressed in patient-derived
cells, we performed western blotting of cell lysates, using
antibodies against synthetic peptides comprising 17–19-
amino-acid N- and C-terminal residues of Pex26p. No
protein bands were detectable, even in normal cells, in-
dicating that Pex26p is a very-low-abundance peroxin
(data not shown). Therefore, we expressed the epitope
Flag-tagged form of Pex26p and its variants in ZP167
cells. Flag-PEX26T35insC was expressed, resulting in a
highly expressed distinct protein band with mass !20 kDa
(fig. 4, left panel [lane 6]). Flag-Pex26pG89R was ap-
parently much lower in the expressed level as compared
with normal Flag-Pex26p (fig. 4, left panel [lanes 1 and
2]), suggesting that this mutant was unstable, presumably
owing to degradation. Flag-Pex26pR98W was likewise
detected in a lesser amount than Flag-Pex26pG89R (fig.
4, left panel [lane 3]), whereas Flag-Pex26pL45P was at
a level similar to normal Flag-Pex26p (fig. 4, left panel
[lane 4]). Flag-PEX26M1T, encoding Flag-Pex26p trun-
cated from 1 to 96 (see the “Material and Methods”
section), was likewise expressed in ZP167, in which the
Pex26p variant was detected as a band with mass ∼27
kDa, in a lesser amount than the normal type (fig. 4, left
panel [lane 5]). This Pex26pM1T appears to be biolog-
ically active (see fig. 3B and table 4). Pex26pG255insT
was normally expressed as an ∼15-kDa protein (fig. 4,
left panel [lane 6]). The results imply that mutations at
Pex26pG89R and Pex26pR98W render Pex26p unstable
and possibly partially degraded, thereby causing the im-
pairment of peroxisome biogenesis in CG8 patients. Dys-
function of Pex26p variants, such as those with L45P,
may arise from other effects, including an impaired in-
teraction with other peroxins. The expressed level of
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Figure 5 Expression of PEX26 in human tissues. Northern blot
analysis of poly(A) RNA (2 mg) from pancreas, kidney, skeletal mus-
cle, liver, lung, placenta, brain, and heart was done with a 32P-labeled
PEX26 cDNA probe. RNA size markers are given at left. b-Actin
cDNA was used to assess RNA load. An actin isoform RNA (1.6 kb)
was also detected in muscle and heart. Exposure for PEX26 was 3 d;
exposure for b-actin was 16 h.
Pex26p variants, including normal Pex26p, was elevated
at 30C (fig. 4, right panel). The relation of the expressed
Flag-Pex26p variants, such as those with T35insC and
G255insT, to the morphological phenotype noted by ex-
pressing the untagged variants (fig. 3B and table 4) re-
mains to be defined.
Tissue Expression of PEX26
The expression level of PEX26 mRNA in different tis-
sues was examined by northern blot analysis. A PEX26
transcript with ∼4.4 kb was detected as a major transcript
in all of human tissues examined (fig. 5). The highest level
of the PEX26 transcripts was noted in kidney, and a rel-
atively high level was detectable in liver, brain, and skele-
tal muscle. In several tissues, such as kidney and liver, a
smaller transcript, with ∼1.8 kb, was also detected. The
PEX26 expression pattern was similar to that of PEX6,
except that the highest level of PEX6 mRNA was in skel-
etal muscle (Yahraus et al. 1996), whereas PEX5 and
PEX7 mRNAs showed distinct expression patterns (Dodt
et al. 1995; Braverman et al. 1997).
Discussion
In the present study, we have demonstrated that im-
pairment of PEX26 is the genetic cause of CG8 PBDs.
The genetic cause of CG8 PBDs had been sought for
more than a decade. Expression of PEX26 variants from
CG8 patients in a pex26 ZP167 nearly reproduced the
phenotypes of the patient-derived fibroblasts, hence con-
firming that impaired PEX26 is the genetic cause of CG8
disorders (table 4). Accordingly, PEX26 is the 12th and
last gene responsible for the PBDs of 12 CGs. The com-
pletion of the search for pathogenic genes responsible
for 12 CGs of PBDs now makes it possible to conduct
prenatal DNA diagnoses in all of the PBD CGs. CG8 is
the third most common among the 11 PBDs and mani-
fests clinically as ZS, NALD, and IRD (table 3) (Moser
et al. 1995; Gould and Valle 2000). We investigated the
cause of the variability of clinical manifestations in CG8
PBDs by analyzing the types and/or sites of mutations
in PEX26, as well as the cell phenotype with respect to
TS peroxisome biogenesis. Fibroblasts from all of the
patients with ZS whom we examined showed defects in
the import of catalase possessing a PTS1-like C-terminal
KANL sequence and PTS2 thiolase, whereas import of
PTS1 proteins was normal. Of the four patients with the
ZS phenotype, a homozygous G89R mutation was iden-
tified in two patients, an undetectable level of PEX26
mRNA was identified in the third patient, and a 1-base
insertion at position 35 in one allele and the other allele
with additional truncation was identified in the fourth
patient. All of these mutations, as well as a mutation pre-
sumably resulting in a lack of detectable PEX26 mRNA,
appear to severely affect Pex26p in terms of functionally
essential configuration and expression level, thus leading
to the severe, ZS-type PBD. Only one type of mutation,
R98W, was identified in two patients with NALD, giving
rise to normal PTS1 import and less efficient import of
catalase and PTS2 protein. Catalase and PTS2-protein
import became more efficient in a TS manner. Similarly,
in the two patients with IRD, we observed normal PTS1
import and TS-type import of catalase and thiolase. Thus,
it is likely that PEX26 mutations conferring the TS phe-
notype are the clinically milder NALD and IRD pheno-
types, whereas those cells that are not TS lead to the severe
ZS phenotype. Similar TS phenotypes were reported for
patients of other CGs who have milder forms of PBDs
(see table 3). It is noteworthy that the most common TS-
type mutation in other peroxins was identified in Pex1p-
defective patients with IRD who carry an allelic mutation
in a codon for G843D (Imamura et al. 1998a; Tamura
et al. 2001; Walter et al. 2001).
PEX26 mutations in the CG8 patients identified here
are mostly located at the region encoding the N-ter-
minal part of Pex26p, implying that this portion plays
a crucial role in peroxisomal-protein import. Impaired
function of these Pex26p variants was assessed by ex-
pression in pex26 ZP167 cells. Pex26p with mutations
(G89R and R98W) showed a phenotype similar to that
seen in the patient-derived fibroblasts (table 4). Mis-
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sense mutations of Pex26p, such as G89R and R98W,
that apparently affect the configuration of Pex26p var-
ied in respect to the TS phenotype; the TS R98W muta-
tion was associated with the NALD phenotype, and the
non-TS mutation was associated with the ZS pheno-
type. Coexpression of Pex26pM1T and Pex26pL45P
reproduced the morphological phenotype observed in
the patient-derived cells, as did PEX26M1T-trans-
fected ZP167, in spite of complete loss of activity of
Pex26pL45P; this implies that Pex26pL45P is not a
dominant-negative mutant. Hence, given functionally
active Pex26pM1T, it is more likely that translation
started at the second, internally located methionine, at
position 96—at least in the expression construct using
a CMV promoter, the product of which migrated in
SDS-PAGE at mass ∼27 kDa. Likewise, coexpression
of Pex26pR98W and Pex26pG255insT showed a phe-
notype similar to that in the patient-derived cells. Con-
trary to such a reproducible phenotype, coexpression
of Pex26pT35insC and Pex26pT35insC/del223-271
failed to show the impaired import of catalase and
PTS2, whereas Pex26pT35insC/del223-271 moderate-
ly represented the phenotype of the patient’s morphol-
ogy. This may be due to a different level of expres-
sion of each mutant Pex26p or translation at Met96 in
transfection of PEX26T35insC. It is more likely that
the T35insC mutation, creating Pex26p with normal
sequence only up to amino acid at position 11, resulted
in the most severely impaired phenotype, ZS. In ad-
dition, expression levels of Pex26p variants identified
in CG8 patients were verified by the expression of Flag-
tagged forms in ZP167 cells. Normal level of expres-
sion was noted in Pex26p with L45P, whereas a lower
level was seen for Pex26p with G89R and R98W. From
this viewpoint, it is conceivable that Pex26p variants
with G89R and R98W reflect partly, if not complete-
ly, the phenotype noted in the patient-derived cells. A
phenotype with missense mutations, G89R and R98W,
as well as the T35insC mutation, creating Pex26p mu-
tant with only normal 11-amino-acid plus distinct 102-
amino-acid sequence, implies that the N-terminal part
plays a role in the function of Pex26p in peroxisome
biogenesis.
These findings raise several possibilities. Pex26p may
play a direct role in the import of matrix proteins and
may be required strictly for the import of catalase and
PTS2 proteins but not for the import of PTS1 proteins.
Alternatively, Pex26p may interact with a translocon
involved in soluble-protein import, such as Pex14p,
Pex13p, and RING peroxins (Fujiki 2000; Gould and
Valle 2000; Otera et al. 2002). It is also possible that
Pex26p may be involved in regulation of translocation
steps of soluble peroxins, such as the PTS1 receptor
Pex5p and the PTS2 receptor Pex7p, as well as Pex1p
and Pex6p of the AAA ATPase family of peroxins (Fu-
jiki 2000; Gould and Valle 2000). As a pivotal role of
Pex26p, we very recently demonstrated that Pex26p
functions in recruiting Pex1p-Pex6p complexes to per-
oxisome membranes (Matsumoto et al. 2003). Its un-
derlying molecular mechanisms and dysfunctions re-
main to be defined.
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